DRL inches up after pact with Integra LifeSciences

Dr Reddy's Laboratories rose 0.83% to Rs 2,645 at 14:26 IST on BSE after the company entered into an exclusive distribution agreement with Integra LifeSciences for two drugs.

The announcement was made during market hours today, 27 March 2017.

Meanwhile, the S&P BSE Sensex was down 132.74 points or 0.45% at 29,288.66.

On the BSE, 15,000 shares were traded on the counter so far as against the average daily volumes of 42,436 shares in the past one quarter. The stock had hit a high of Rs 2,649.40 and a low of Rs 2,617.95 so far during the day.

The stock had hit a 52-week high of Rs 3,689 on 20 July 2016 and a 52-week low of Rs 2,560 on 22 March 2017. It had underperformed the market over the past one month till 24 March 2017, sliding 9.24% compared with the Sensex's 1.83% rise. The scrip had also underperformed the market over the past one quarter, declining 12.65% as against the Sensex's 12.98% rise.

The large-cap company has equity capital of Rs 82.87 crore. Face value per share is Rs 5.

Dr Reddy's Laboratories (DRL) and Integra LifeSciences Holdings Corporation, a leading global medical technology company, announced that they have entered into an exclusive distribution agreement. Under the agreement, DRL will market and distribute DuraGen Plus and Suturable DuraGen Dural Regeneration Matrices for use in patients in India.

M. V. Ramana, Executive Vice President and Head of Emerging Markets & India Business, DRL said, the company is delighted to partner with Integra LifeSciences. With the launch of DuraGen, it looks forward to building its presence in the segment of regenerative technologies and making a difference to the lives of patients undergoing neurosurgery.

Dr Reddy's Laboratories' consolidated net profit fell 15.9% to Rs 492.30 crore on 6.6% fall in net sales to Rs 3706.50 crore in Q3 December 2016 over Q3 December 2015.

Dr Reddy's Laboratories is an integrated global pharmaceutical company.

Powered by Capital Market - Live News